Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 24, 2026

Economist Justin Wolfers Says Trump Policies Are 'Hurting The American People And He Doesn't Want To Admit It,' Instead Calling It 'Fake Inflation'

View original at finance.yahoo.com
Economist Justin Wolfers Says Trump Policies Are 'Hurting The American People And He Doesn't Want To Admit It,' Instead Calling It 'Fake Inflation' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expensive energy could persist for years without conflict resolution

    60% confidence
  • Oil prices are well below worst-case predictions of $250-$300 per barrel, currently around $90

    60% confidence
  • Current inflation is 'fake inflation' because of fuel and energy prices

    60% confidence
  • Without a satisfactory resolution to the conflict, energy price concerns will remain long-term

    60% confidence
  • Inflation fears are overblown

    60% confidence
  • Cost pressures Americans are feeling are very real, not fake

    60% confidence
  • Gas prices are really expensive right now and unavoidably noticeable

    60% confidence
  • Trump's policies are hurting the American people and he doesn't want to admit it

    60% confidence
  • Market uncertainty is reflected in both current oil prices and long-term expectations

    60% confidence
  • Americans will be 'very impressed' by what happens over the next week or so

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com